Heidelberg Pharma AG 0QW5.L Stock
Heidelberg Pharma AG Price Chart
Heidelberg Pharma AG 0QW5.L Financial and Trading Overview
| Heidelberg Pharma AG stock price | 2.99 EUR |
| Previous Close | 3.84 EUR |
| Open | 0 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0 - 0 EUR |
| 52 Week Range | 0 - 5.82 EUR |
| Volume | 80 EUR |
| Avg. Volume | 9 EUR |
| Market Cap | 956.44K EUR |
| Beta (5Y Monthly) | -0.248659 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.814 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0QW5.L Valuation Measures
| Enterprise Value | 118.19M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.047829065 |
| Price/Book (mrq) | 2.871517 |
| Enterprise Value/Revenue | 5.91 |
| Enterprise Value/EBITDA | -6.873 |
Trading Information
Heidelberg Pharma AG Stock Price History
| Beta (5Y Monthly) | -0.248659 |
| 52-Week Change | -29.73% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.82 EUR |
| 52 Week Low | 0 EUR |
| 50-Day Moving Average | 4.77 EUR |
| 200-Day Moving Average | 4.77 EUR |
0QW5.L Share Statistics
| Avg. Volume (3 month) | 9 EUR |
| Avg. Daily Volume (10-Days) | 8 EUR |
| Shares Outstanding | 28.13M |
| Float | 5.86M |
| Short Ratio | N/A |
| % Held by Insiders | 83.09% |
| % Held by Institutions | 3.02% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor | 1.046408:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | November 30, 2022 |
| Most Recent Quarter (mrq) | February 28, 2023 |
| Next Fiscal Year End | November 30, 2023 |
Profitability
| Profit Margin | -95.10% |
| Operating Margin (ttm) | -89.051% |
| Gross Margin | 72.50% |
| EBITDA Margin | -85.99% |
Management Effectiveness
| Return on Assets (ttm) | -20.77% |
| Return on Equity (ttm) | -63.60% |
Income Statement
| Revenue (ttm) | 20M EUR |
| Revenue Per Share (ttm) | 0.5 EUR |
| Quarterly Revenue Growth (yoy) | 189.90% |
| Gross Profit (ttm) | 13.96M EUR |
| EBITDA | -17195646 EUR |
| Net Income Avi to Common (ttm) | -19019120 EUR |
| Diluted EPS (ttm) | -0.814 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 65.01M EUR |
| Total Cash Per Share (mrq) | 1.4 EUR |
| Total Debt (mrq) | 10.37M EUR |
| Total Debt/Equity (mrq) | 17.24 EUR |
| Current Ratio (mrq) | 3.427 |
| Book Value Per Share (mrq) | 1.292 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -13080750 EUR |
| Levered Free Cash Flow (ttm) | -11034410 EUR |
Profile of Heidelberg Pharma AG
| Country | United Kingdom |
| State | N/A |
| City | Ladenburg |
| Address | Gregor-Mendel-Strasse 22 |
| ZIP | 68526 |
| Phone | 49 6203 1009 0 |
| Website | https://heidelberg-pharma.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 100 |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors; HDP-XX for the treatment of solid/hematological tumors; MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; and TAK-ATACs for oncology. It is also developing TLX250-CDx, a diagnostic antibody for diagnosing renal cancer that is in Phase III trials; urothelial carcinoma or bladder cancer, which is in Phase II study; and triple-negative breast cancer that is in Phase II study. In addition, the company develops TLX250 (girentuximab), a diagnostic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.
Q&A For Heidelberg Pharma AG Stock
What is a current 0QW5.L stock price?
Heidelberg Pharma AG 0QW5.L stock price today per share is 2.99 EUR.
How to purchase Heidelberg Pharma AG stock?
You can buy 0QW5.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Heidelberg Pharma AG?
The stock symbol or ticker of Heidelberg Pharma AG is 0QW5.L.
How many shares does Heidelberg Pharma AG have in circulation?
The max supply of Heidelberg Pharma AG shares is 257.8K.
What is Heidelberg Pharma AG Price to Earnings Ratio (PE Ratio)?
Heidelberg Pharma AG PE Ratio is now.
What was Heidelberg Pharma AG earnings per share over the trailing 12 months (TTM)?
Heidelberg Pharma AG EPS is -0.814 EUR over the trailing 12 months.